Core Viewpoint - The approval of the siRNA drug SYH2061 by the FDA marks a significant milestone for the company, indicating potential growth in the treatment of complement-mediated diseases [1] Company Summary - The stock price of the company, 石药集团 (Stone Pharmaceutical Group), increased by over 3%, reaching 7.78 HKD with a trading volume of 323 million HKD [1] - The company announced that its self-developed siRNA drug, SYH2061 injection, has received FDA approval to conduct clinical trials in the United States [1] - The product has also been approved by the National Medical Products Administration of China to initiate clinical trials in China by October 2025 [1] Product Details - SYH2061 is a chemically modified siRNA drug designed for liver-targeted delivery via GalNAc conjugation, aimed at reducing complement protein C5 levels [1] - The drug is administered subcutaneously and is the first domestically developed long-acting siRNA drug targeting C5 to enter clinical trials in China [1] - It is intended for the treatment of IgA nephropathy and other complement-mediated diseases, showcasing a promising approach to gene silencing through optimized sequences and chemical modifications [1]
港股异动 | 石药集团(01093)涨超3% SYH2061注射液在美国获批临床